assurance maladie maternité – Non-remboursement du Slenyto

This written question concerns the non-reimbursement of the drug Slenyto by French health insurance. It seeks clarification on the reasons behind this decision and its impact on patients. The question affects patients prescribed Slenyto, their families, and healthcare providers. It highlights potential issues in drug accessibility and the national health insurance system's coverage.